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Abstract A series of new benzimidazole and benzotriazole
derivatives containing a tetrazole moiety was synthesized
by N-alkylation of 5-aryltetrazole with 4,5,6,7-tetrabromo-
1-(3-chloropropyl)-1H-benzimidazole and 4,5,6,7-tetra-
bromo-2-(3-chloropropyl)-2H-benzotriazole. The reaction
was regioselective and mostly 2,5-disubstituted tetrazole
derivatives were obtained. The effect of all synthesized
compounds on human recombinant casein kinase 2alpha
subunit (rhCK2a) and cytotoxicity against human T-cell
lymphoblast (CCRF-CEM) and breast adenocarcinoma
(MCF-7) cell lines were evaluated. The results have shown
that many of the synthesized compounds exhibit significant
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Introduction
Azole derivatives have been reported to possess diverse
biological activity and are widely used in a medicinal
chemistry [1–3]. Nowadays, many research groups focus on
designing and synthesis of compounds containing two or
more azoles, in search for obtaining more active compounds.
Many structures containing indole, benzotriazole, or benz-
imidazole linked with tetrazolyl substituent have been
obtained and characterized. It was shown that the attachment
of a tetrazolyl substituent to indole derivatives resulted in an
increase of both; antibacterial activity against Gram-positive
bacteria (Bacillus subtilis, Streptococcus lactis) and Gram-
negative bacteria (Escherichia coli, Pseudomonas aerugi-
nosa), and antifungal activity against Candida albicans,
Aspergillus niger, and Penicillium sp. [4]. Furthermore, it is
known, that certain indolyltetrazole derivatives exhibit sig-
nificant anticancer activity against human liver carcinoma
cell line (HepG2) [5]. The incorporation of the tetrazole
moiety into benzotriazole and benzimidazole derivatives
resulted in the improvement of biological action of the
compound. Structures containing both benzotriazole and
tetrazole moiety in addition to antibacterial and antifungal
properties exhibit significant, anticonvulsant, anti-inflam-
matory, and anti-nociceptive activity [6, 7]. Compound
2-[2-(5-phenyl-1H-tetrazol-1-yl)phenyl]-1H-benzimidazole
exhibits significant antibacterial (against Staphylococcus
aureus and Escherichia coli) and antifungal (against C.
albicans and A. niger) activity comparable with cipro-
floxacin and fluconazole, respectively [8]. Similar properties
are also described for 2-(a-p-substituted phenyl-a-benzimi-
dazolo)methyl-1,2,3,4-tetrazole [9] and other derivatives
[10, 11]. Furthermore, there are known benzimidazole-te-
trazole derivatives, which show anti-hypertensive activity
compared with losartan and telmisartan [12–14]. There are
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also obtained benzimidazole derivatives bearing a tetrazole
ring, that reveal moderate anti-asthmatic, and anti-diabetic
activity as well as antioxidant and antitumor activity against
mice Dalton’s lymphoma ascites (DLA), human breast
adenocarcinoma (MCF-7), and human colon adenocarci-
noma (HCT) cell lines [11, 15–18].
Taking into consideration the biological importance of
benzimidazole, benzotriazole, and tetrazole derivatives and
fact that the fusion of various tetrazoles to azoles generally
leads to an increase of the biological activity, we decided
to synthesize a new group of compounds containing
benzimidazole/benzotriazole and tetrazole moieties and
evaluate their cytotoxic effect on two human cancer cell
lines: T-cell lymphoblast (CCRF-CEM) and breast adeno-
carcinoma (MCF-7). Knowing that 4,5,6,7-tetrabromo-1H-
benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimi-
dazole (TBBi) derivatives are inhibitors of casein kinase
CK2 [19, 20], which is significantly increased in many




Synthesis of the intermediate and target compounds was
performed according to the Scheme 1. The starting poly-
brominated benzimidazole 1 and benzotriazole 2 were
obtained according to the described in literature methods
[23, 24]. Substrates 3 and 4 were obtained by N-alkylation
of 4,5,6,7-tetrabromo-1H-benzimidazole (1) or 4,5,6,7-
tetrabromo-2H-benzotriazole (2) with 1-bromo-3-chloro-
propane. The alkylation was performed in the presence of
KOH as a base in acetonitrile at 60 C [25]. The new
azoles 6a–6d, 7a–7d, and 8a–8d were synthesized by
N-alkylation of 5-aryltetrazoles 5a–5d with 4,5,6,7-tetra-
bromo-1-(3-chloropropyl)-1H-benzimidazole (3) and
4,5,6,7-tetrabromo-2-(3-chloropropyl)-2H-benzotriazole (4).
The 5-aryltetrazoles 5a–5d were obtained from commer-
cially available nitriles, NaN3, and NH4Cl in DMF
according to the described method [26].
First attempt of synthesis of compounds 6a and 7a was
performed in n-butanol in the presence of K2CO3 and KI at
90 C, but in these conditions products were not formed. In
other approach only K2CO3 and CH3CN were used. The
reaction was performed at reflux and the progress was
monitored by thin-layer chromatography (Scheme 1).
Products 6a and 7a were obtained with total yield 86 %. The
ratio of 2,5-disubstituted isomer 6a to 1,5-disubstituted
isomer 7a equaled 7.42 to 1, and showed the regioselectivity
of the reaction. In this manner N-alkylation of other arylte-
trazole derivatives 5b–5d was performed. In all cases
reactions were regioselective and formation of 2,5-disub-
stituted tetrazoles was preferred. Additionally, the weight
ratio of 2,5-isomer 6a–6d to 1,5-isomer 7a–7d depended on
aryl substituent in the tetrazole ring and range from 13.5/1 to
2.8/1. The times, yields, and isomers ratios are summarized
in Table 1. All isomeric products 6a–6d and 7a–7d were
separated and purified by column chromatography on silica
gel. Their structures were elucidated on the basis of 1H
NMR, 13C NMR, IR, and HRMS spectral data.
The same procedure was applied for the synthesis of
4,5,6,7-tetrabromo-2H-benzotriazole derivatives 8a–8d.
The progress of the reaction was monitored by TLC using
chloroform:cyclohexane (9:1 v/v) as an eluent. Products
were purified three times by column chromatography.
There is no doubt, that repeated purification contributed to
lower yields of the reactions (Table 1). In this case only
2,5-disubstituted tetrazoles were obtained, what is consis-
tent with our previous studies [27].
Cytotoxicity assay
The effect of synthesized compounds on viability of human
T lymphoblast leukemia (CCRF-CEM) and human breast
adenocarcinoma (MCF-7) cell lines was evaluated using
MTT assay [28]. The cytotoxicity of 4,5,6,7-tetrabromo-1H-
benzimidazole (1) and its derivatives 3, 6a–6d, and 7a–7d
was determined after 24 h and 48 h treatment at 10, 25, 50,
and 100 lM concentration of each compound (Tables 2, 3).
In the case of the leukemia cell line (CCRF-CEM), the
highest cytotoxicity exhibited compounds 7a and 7d, that
at the 25 lM concentration caused a complete (7a) or
almost complete (7d) loss of cell viability after 48 h
treatment. Worth attention are also compounds 7b, 7c, that
effectively inhibited cell growth at the 50 lM concentra-
tion. As can be seen from the results presented in the
Table 2 the cytotoxic activity of investigated compounds
depended on their structure. All 1,5-disubsituted tetrazoles
7a–7d appeared more cytotoxic than their 2,5-disubstituted
isomers 6a–6d. It has to be pointed out, that compounds
7a–7d exhibited higher cytotoxicity than TBBi (1) and its
3-chloropropyl derivative 3.
Human breast adenocarcinoma cell line (MCF-7)
reveals higher resistance for all tested compounds as
compared with leukemia cell line (Table 3). All benzimi-
dazole derivatives exhibited lower cytotoxicity against
MCF-7 than it was observed for CCRF-CEM cell line, and
higher compound concentration and/or prolongation of
treatment time to 48 h were necessary to observe signifi-
cant decrease of cell viability. The most active compounds
were 7a–7d (25 lM) and 6b–6d (50 lM). Moreover,
comparing the cytotoxicity of TBBI (1) and 4,5,6,7-tetra-
bromo-1-(3-chloropropyl)-1H-benzimidazole (2), with the
effect of these compounds, it appeared that synthesized
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derivatives 7a–7d and 6b–6d reduced the viability of
MCF-7 cells more effectively.
Similar experiments with 4,5,6,7-tetrabromo-2H-ben-
zotriazole (2) and its derivatives 4 and 8a–8d were
performed. The results are summarized in Tables 4 and 5.
In contrary to above-described compounds, the benzotria-
zole derivatives 8a–8d exhibited lower cytotoxicity against
CCRF-CEM then against MCF-7 cancer cell lines.
For the CCRF-CEM cell line the highest cytotoxicity
was observed for compounds 8a and 8c, which at 50 lM
concentration, regardless of incubation time, reduced the


















































































(a) KOH, MeOH, BrCH2CH2CH2Cl, CH3CN, 60 
oC 
(b) K2CO3, CH3CN, reflux
Table 1 The reaction times and yields of the compounds 6a–6d, 7a–
7d, and 8a–8d
Comp Ar Time/h Yield/% Isomers ratio (6/7)
6a?7a C6H5– 48 86 7.42/1
6b?7b 4-CH3–C6H4– 48 89 7.41/1
6c?7c 4-Cl–C6H4– 48 80 13.5/1
6d?7d 2-Cl–C6H4– 48 78 2.8/1
8a C6H5– 48 57 1/0
8b 4-CH3–C6H4– 48 46 1/0
8c 4-Cl–C6H4– 48 54 1/0
8d 2-Cl–C6H4– 240 63 1/0
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For the MCF-7 the most significant inhibitory effect was
observed for compounds 8a–8c, which showed cytotoxicity
at all investigated concentrations in time-dependent man-
ner (Table 5). These compounds were also more cytotoxic
then TBBt (2) and 4,5,6,7-tetrabromo-2-(3-chloropropyl)-
2H-benzotriazole (4).
It can be concluded that the viability of tested human
cancer cell lines was reduced by all synthesized com-
pounds in the concentration- and time-dependent manner.
It is also evident, that these close structurally related
molecules displayed remarkable differences in cytotoxic-
ity. Benzimidazole derivatives containing tetrazole ring
appeared more cytotoxic against both cell lines then their
benzotriazole analogs. It has to be pointed out, that many of
the synthesized azoles (7a–7d, 6a–6d, 8a–8c) showed
higher cytotoxicity than basic compounds TBBi 1 or TBBt
2 and their corresponding chloropropyl derivatives 3 and 4,
what confirms, that the aryltetrazolyl substituent can
increase the biological activity.
To explain the molecular mechanism of action of the
synthesized tetrazole derivatives, their effect on the activity
of human recombinant casein kinase 2a subunit (rhCK2a)
was estimated. Unexpectedly, all obtained derivatives did
not inhibit kinase activity at 1–20 micromolar concentra-
tions, what indicates that this enzyme is not a target for
these compounds. It is known that TBBt and TBBi and
their derivatives affect other kinases and proteins not
dependent on ATP, i.e. quinone reductase [29], or
Table 2 Effect of 4,5,6,7-tetrabromo-1H-benzimidazole (1) and its derivatives 3, 6a–6d, and 7a–7d on viability of CCRF-CEM cells
Comp CCRF-CEM cell viability % ± SD
Incubation time 24 h Incubation time 48 h
10 lM 25 lM 50 lM 100 lM 10 lM 25 lM 50 lM 100 lM
1 112 ± 10 51 ± 2 15 ± 5 1 ± 0 90 ± 9 23 ± 2 3 ± 1 0 ± 0
3 97 ± 7 67 ± 10 4 ± 1 1 ± 1 103 ± 5 69 ± 3 3 ± 2 0 ± 0
6a 106 ± 6 73 ± 10 4 ± 1 6 ± 1 105 ± 14 64 ± 1 0 ± 0 1 ± 0
6b 108 ± 8 92 ± 0.5 18 ± 3 9 ± 2 113 ± 5 77 ± 0 6 ± 1 1 ± 1
6c 103 ± 11 91 ± 6 45 ± 9 31 ± 4 124 ± 6 102 ± 1 31 ± 3 15 ± 2
6d 102 ± 8 96 ± 2 68 ± 10 52 ± 1 104 ± 3 89 ± 1 42 ± 3 31 ± 4
7a 67 ± 9 4 ± 1 2 ± 1 2 ± 0 57 ± 7 0 ± 0 0 ± 0 0 ± 0
7b 82 ± 5 7 ± 1 6 ± 2 6 ± 3 68 ± 7 9 ± 1 1 ± 0 0 ± 0
7c 90 ± 12 19 ± 3 7 ± 2 6 ± 2 66 ± 7 12 ± 3 0 ± 0 0 ± 0
7d 65 ± 5 1 ± 0.6 2 ± 1 2 ± 2 51 ± 12 1 ± 0 0 ± 0 0 ± 0
Data are presented as mean ± SD in three repeated experiments
Table 3 Effect of 4,5,6,7-tetrabromo-1H-benzimidazole (1) and its derivatives 3, 6a–6d, and 7a–7d on viability of MCF-7 cells
Comp MCF-7 cell viability % ± SD
Incubation time 24 h Incubation time 48 h
10 lM 25 lM 50 lM 100 lM 10 lM 25 lM 50 lM 100 lM
1 89 ± 2 71 ± 3 56 ± 0 44 ± 2 88 ± 4 57 ± 4 37 ± 5 25 ± 2
3 97 ± 4 88 ± 2 45 ± 1 6 ± 2 96 ± 5 66 ± 1 31 ± 10 4 ± 2
6a 104 ± 1 110 ± 1 47 ± 3 40 ± 5 103 ± 2 70 ± 4 31 ± 6 19 ± 3
6b 103 ± 4 83 ± 3 21 ± 1 7 ± 1 98 ± 4 67 ± 2 19 ± 5 2 ± 0
6c 98 ± 4 59 ± 3 19 ± 2 5 ± 2 97 ± 8 76 ± 0 13 ± 7 3 ± 1
6d 100 ± 4 80 ± 3 25 ± 5 9 ± 3 98 ± 3 67 ± 4 25 ± 2 19 ± 6
7a ND ND ND ND 64 ± 2 22 ± 4 16 ± 2 10 ± 1
7b 88 ± 5 77 ± 6 75 ± 0 52 ± 4 87 ± 5 28 ± 1 29 ± 3 28 ± 3
7c 98 ± 3 62 ± 7 68 ± 1 63 ± 0 87 ± 3 29 ± 0 21 ± 6 20 ± 1
7d 89 ± 1 69 ± 9 68 ± 3 61 ± 5 91 ± 6 45 ± 1 25 ± 4 16 ± 1
Data are presented as mean ± SD in three repeated experiments
ND not determined
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interacting with ATP, i.e., heat shock proteins HSP90B or
HSP7C [30] therefore further investigation of inhibitory
activity and protein interactions of obtained compounds are
needed.
Conclusion
A series of twelve new azoles was synthesized by the
reaction of 4,5,6,7-tetrabromo-1-(3-chloropropyl)-1H-ben-
zimidazole (3) and 4,5,6,7-tetrabromo-2-(3-chloropropyl)-
2H-benzotriazole (4) with various 5-aryltetrazoles 5a–5d.
Products were obtained in relatively short time and with
satisfactory yields. In all reactions, formation of 2,5-di-
substituted tetrazoles was preferred. For all compounds, the
influence on human casein kinase CK2a subunit and
cytotoxic activity against human CCRF-CEM and MCF-7
cancer cell lines were evaluated. All synthesized benzim-
idazole derivatives exhibited higher cytotoxicity against
CCRF-CEM cells than against MCF-7 cells, and in the case
of benzotriazole derivatives opposite trend was observed.
According to our expectations, the introduction of arylte-
trazole moiety into the alkyl side chain of the
benzimidazole or benzotriazole resulted in higher
cytotoxicity as compared to the nonsubstituted TBBi (1)
and TBBt (2), and its analogs 3 and 4. It has been proved
that the cytotoxic effect of synthesized compounds is not
caused by the interaction with rhCK2a subunit.
Experimental
All reagents, solvents, and chemicals were purchased from
POCH (Gliwice, Poland), Merck (Darmstadt, Germany),
and Sigma-Aldrich (Munich, Germany) and were at ana-
lytical grade. Dimethyl sulfoxide (DMSO), molecular
biology grade used as a solvent for all stocks of the
chemical agents was obtained from Roth (Karlsruhe-
Rheinhafen, Germany). The reactions were monitored by
TLC aluminum plates with silica gel Kieselgel 60 F254
(Merck, Darmstadt, Germany, 0.2 mm thickness film)
using UV light as visualizing agent. Column chromatog-
raphy was performed using Kieselgel 60 (Merck,
0.040–0.063 mm). Melting points were determined in open
glass capillary tubes. IR spectra were taken on a Specord
M80 instrument (Carl Zeiss, Jena, Germany). HRMS
spectra were recorded on a Micro-mass ESI Q-ToF Premier
instrument (Micromass UK Limited, Manchester UK). 1H
Table 4 Effect of 4,5,6,7-tetrabromo-2H-benzotriazole (2) and its derivatives 4 and 8a–8d on viability of CCRF-CEM cells
Comp CCRF-CEM cell viability % ± SD
Incubation time 24 h Incubation time 48 h
25 lM 50 lM 100 lM 25 lM 50 lM 100 lM
2 94.3 ± 1.2 62.1 ± 4.2 25.4 ± 3.5 78.9 ± 3.0 54.6 ± 1.8 7.5 ± 0.6
4 81.9 ± 4.0 85.7 ± 5.1 90.6 ± 2.7 82.1 ± 8.1 78.2 ± 0.6 76.6 ± 5.6
8a 81.5 ± 4.6 49.7 ± 4.7 34.7 ± 4.8 73.8 ± 4.7 41.0 ± 1.8 35.5 ± 0.9
8b 89.1 ± 3.7 70.9 ± 0.8 67.1 ± 3.7 93.8 ± 0.6 74.7 ± 3.4 70.1 ± 3.1
8c 46.9 ± 2.2 40.7 ± 3.7 31.0 ± 6.0 48.6 ± 3.8 39.4 ± 1.7 12.9 ± 1.8
8d 88.7 ± 0.5 88.1 ± 6.3 94.3 ± 8.0 94.0 ± 5.5 76.9 ± 4.0 70.9 ± 1.9
Data are presented as mean ± SD in three repeated experiments
Table 5 Effect of 4,5,6,7-tetrabromo-2H-benzotriazole (2) and its derivatives 4 and 8a–8d on viability of MCF-7 cells
Comp MCF-7 cell viability % ± SD
Incubation time 24 h Incubation time 48 h
25 lM 50 lM 100 lM 25 lM 50 lM 100 lM
2 102.1 ± 5.6 95.1 ± 2.4 77.9 ± 3.9 93.9 ± 1.4 85.6 ± 1.6 51.1 ± 0.8
4 74.1 ± 2.7 66.8 ± 1.9 59.2 ± 4.7 53.4 ± 1.0 55.0 ± 3.6 60.3 ± 5.0
8a 67.0 ± 2.2 47.0 ± 1.6 25.3 ± 2.0 60.6 ± 2.9 30.7 ± 1.8 3.7 ± 0.7
8b 57.4 ± 1.7 49.7 ± 3.3 33.8 ± 2.3 40.0 ± 2 35.3 ± 2.3 19.5 ± 3.4
8c 38.2 ± 1.3 23.0 ± 2.6 5.1 ± 2.4 13.5 ± 2.0 2.8 ± 0.4 1.3 ± 0.4
8d 80.3 ± 3.0 70.8 ± 1.4 52.0 ± 3.3 64.8 ± 2.4 58.1 ± 2.4 32.7 ± 3.0
Data are presented as mean ± SD in three repeated experiments
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(400 MHz) and 13C NMR (100 MHz) spectra were recor-
ded on a Mercury 400 MHz spectrometer (Varian,
California, USA) in CDCl3 solution; chemical shifts (d) are
reported in ppm; coupling constants (J) are given in hertz
(Hz).
General procedure for N-alkylation of 5-aryltetrazoles
5a–5d with 4,5,6,7-tetrabromo-1-(3-chloropropyl)-1H-
benzimidazole (3) and 4,5,6,7-tetrabromo-2-(3-
chloropropyl)-2H-benzotriazole (4)
A mixture of appropriate 5-aryltetrazole (5a–5d, 1 mmol)
and 0.18 g K2CO3 (1 mmol) in 30 cm
3 acetonitrile was
stirred and heated to reflux. After 30 min 0.26 g 4,5,6,7-
tetrabromo-1-(3-chloropropyl)-1H-benzimidazole (3,
0.5 mmol) or 0.25 g 4,5,6,7-tetrabromo-2-(3-chloro-
propyl)-2H-benzotriazole (4, 0.5 mmol) was added and the
reaction mixture was stirred at reflux. The progress of the
reaction was monitored by TLC with chloroform–methanol
9:1 v/v (in the case of benzimidazole derivatives) and
chloroform:cyclohexane 9:1 v/v (in the case of benzotria-
zole derivatives) as the eluent. After completion of the
reaction the mixture was cooled in an ice bath and 20 cm3
of chloroform was added. The inorganic solids were fil-
tered off and the solvent was evaporated. Products 6a–6d
and 7a–7d were separated and purified using column
chromatography on silica gel with a chloroform–methanol
(9:1 v/v) as the eluent. Products 8a–8d were purified three
times on column chromatography on silica gel with a
chloroform-hexane (9:1 v/v) and cyclohexane-ethyl acetate
(10:3 v/v) as the eluent. The combined fractions of each
product were concentrated and analyzed.
4,5,6,7-Tetrabromo-1-[3-(5-phenyl-2H-tetrazol-2-yl)pro-
pyl]-1H-benzimidazole (6a, C17H12Br4N6)
Yield: 0.2353 g (76 %); colorless crystals; m.p.:
174–176 C; 1H NMR (400 MHz, CDCl3): d = 8.16 (brs,
1H, CH), 8.12–8.14 (m, 2H, Ar), 7.50–7.51 (m, 3H, Ar),
4.69–4.72 (m, 2H, CH2N), 4.60–4.62 (m, 2H, CH2NCH),
2.64–2.67 (m, 2H, CH2CH2CH2) ppm;
13C NMR
(100 MHz, CDCl3): d = 165.49, 147.04, 144.14, 130.93,
130.65, 129.01, 126.81, 126.79, 124.13, 122.36, 117.82,
105.96, 49.24, 43.75, 31.44 ppm; IR (nujol): v = 1525,
1493, 1452, 1401, 1353, 1197, 1153, 1102, 1070, 1051,




Yield 0.2475 g (78 %); colorless crystals; m.p.:
126–128 C; 1H NMR (400 MHz, CDCl3): d = 8.23 (brs,
1H, CH), 8.00–8.02 (m, 2H, Ar), 7.30–7.32 (m, 2H, Ar),
4.68–4.71 (m, 2H, CH2N), 4.60–4.64 (m, 2H, CH2NCH),
2.64–2.67 (m, 2H, CH2CH2CH2), 2.43 (s, 3H, CH3) ppm;
13C NMR (100 MHz, CDCl3): d = 165.59, 147.07, 140.90,
130.92, 129.70, 126.70, 124.22, 124.03, 122.46, 117.72,
106.03, 49.18, 43.83, 31.44, 21.53 ppm; IR (nujol):
v = 1617, 1579, 1528, 1449, 1410, 1340, 1200, 1165,
1095, 1070, 1041, 1025, 984, 946 cm-1; HRMS (ESI-
TOF): m/z = 634.8370 ([M ? 1]?).
4,5,6,7-Tetrabromo-1-[3-[5-(4-chlorophenyl)-2H-tetrazol-
2-yl]propyl]-1H-benzimidazole (6c, C17H11Br4ClN6)
Yield 0.243 g (74 %); colorless crystals; m.p.:
155–157 C; 1H NMR (400 MHz, CDCl3): d = 8.12 (brs,
1H, CH), 8.05–8.07 (m, 2H, Ar), 7.47–7.49 (m, 2H, Ar),
4.69–4.72 (m, 2H, CH2N), 4.60–4.64 (m, 2H, CH2NCH),
2.64–2.70 (m, 2H, CH2CH2CH2) ppm;
13C NMR
(100 MHz, CDCl3); d = 164.62, 146.95, 144.13, 136.74,
130.91, 129.33, 128.06, 125.31, 124.18, 122.41, 117.86,
105.94, 49.39, 43,80, 31.34 ppm; IR (nujol): v = 1608,
1576, 1550, 1493, 1442, 1417, 1340, 1204, 1168, 1092,
1051, 1016, 997, 978, 943 cm-1; HRMS (ESI-TOF): m/
z = 654.7910 ([M ? 1]?).
4,5,6,7-Tetrabromo-1-[3-[5-(2-chlorophenyl)-2H-tetrazol-
2-yl]propyl]-1H-benzimidazole (6d, C17H11Br4ClN6)
Yield 0.1877 g (57 %); colorless crystals; m.p.:
149–151 C; 1H NMR (400 MHz, CDCl3): d = 8.23 (s,
1H, CH), 7.99–8.01 (m, 1H, Ar), 7.55–7.57 (m, 1H, Ar),
7.42–7.45 (m, 2H, Ar), 4.72–4.75 (m, 2H, CH2N),
4.65–4.68 (m, 2H, CH2NCH), 2.64–2.70 (m, 2H, CH2CH2-
CH2) ppm;
13C NMR (100 MHz, CDCl3): d = 163.63,
147.18, 144.21, 132.92, 131.39, 131.25, 130.96, 127.08,
125.92, 124.10, 122.36, 117.83, 105.98, 49.18, 43.63,
31.56 ppm; IR (nujol): v = 1598, 1569, 1525, 1496, 1449,
1410, 1366, 1340, 1197, 1168, 1130, 1092, 1064, 1041,




Yield 0.0317 g (10 %); colorless crystals; m.p.:
116–118 C; 1H NMR (400 MHz, CDCl3): d = 8.04 (s,
1H, CH), 7.55–7.60 (m, 3H, Ar), 7.49–7.53 (m, 2H, Ar),
4.62–4.66 (m, 2H, CH2N), 4.42–4.46 (m, 2H, CH2NCH),
2.46–2.53 (m, 2H, CH2CH2CH2) ppm;
13C NMR
(100 MHz, CDCl3): d = 154.45, 146.74, 144.14, 131.62,
130.83, 129.44, 1286.52, 124.19, 123.26, 122.43, 117.87,
105.86, 44.19, 43.76, 31.85 ppm; IR (nujol): v = 1576,
1541, 1493, 1468, 1449, 1404, 1379, 1353, 1197, 1178,
1130, 1105, 1073, 1038, 1019, 946 cm-1; HRMS (ESI-
TOF): m/z = 620.8217 ([M ? 1]?).
4,5,6,7-Tetrabromo-1-[3-[5-(4-methylphenyl)-1H-tetrazol-
1-yl]propyl]-1H-benzimidazole (7b, C18H14Br4N6)
Yield 0.0334 g (10 %); colorless crystals; m.p.:
192–193 C; 1H NMR (400 MHz, CDCl3): d = 8.04 (s,
1H, CH), 7.46–7.48 (m, 2H, Ar), 7.29–7.31 (m, 2H, Ar),
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4.62–4.65 (m, 2H, CH2N), 4.42–4.45 (m, 2H, CH2NCH),
2.49–2.51 (m, 2H, CH2CH2CH2), 2.44 (s, 3H, CH3) ppm;
13C NMR (100 MHz, CDCl3): d = 154.47, 146.76, 144.13,
142.24, 130.86, 130.12, 128.37, 124.16, 122.39, 120.25,
117.85, 105.80, 44.21, 43.78, 31.80, 21.57 ppm; IR (nujol):
v = 1620, 1582, 1554, 1525, 1490, 1480, 1452, 1407,
1379, 1353, 1185, 1130, 1108, 1038, 949, 905 cm-1;
HRMS (ESI-TOF): m/z = 634.8370 ([M ? 1]?).
4,5,6,7-Tetrabromo-1-[3-[5-(4-chlorophenyl)-1H-tetrazol-
1-yl]propyl]-1H-benzimidazole (7c, C17H11Br4ClN6)
Yield 0.018 g (6 %); colorless crystals; m.p.: 214–215 C;
1H NMR (400 MHz, CDCl3): d = 8.08 (s, 1H, CH),
7.50–7.57 (m, 4H, Ar), 4.66–4.69 (m, 2H, CH2N),
4.41–4.45 (m, 2H, CH2NCH), 2.50–2.53 (m, 2H, CH2CH2-
CH2) ppm;
13C NMR (100 MHz, CDCl3): d = 153.58,
146.70, 144.13, 138.29, 130.79, 129.89, 129.82, 124.27,
122.56, 121.63, 117.94, 105.80, 44.29, 43.69, 31.77 ppm;
IR (nujol): v = 1598, 1449, 1404, 1356, 1185, 1121, 1089,




Yield 0.066 g (20 %); colorless crystals; m.p.: 83–86 C;
1H NMR (400 MHz, CDCl3): d = 8.01 (s, 1H, CH),
7.50–7.53 (m, 2H, Ar), 7.40–7.42 (m, 2H, Ar), 4.61–4.65
(m, 2H, CH2N), 4.20–4.24 (m, 2H, CH2NCH), 2.41–2.45
(m, 2H, CH2CH2CH2) ppm;
13C NMR (100 MHz, CDCl3):
d = 152.68, 146.74, 144.13, 133.48, 133.01, 131.66,
130.79, 130.28, 127.58, 124.19, 123.14, 122.44, 117.86,
105.89, 44.07, 43.89, 31.53 ppm; IR (nujol): v = 1601,
1525, 1487, 1449, 1401, 1344, 1165, 1134, 1111, 1080,




Yield 0.173 g (57 %); colorless crystals; m.p.: 185–189 C
(dec.); 1H NMR (400 MHz, DMSO-d6): d = 7.67–7.69 (m,
2H, Ar), 7.41–7.44 (m, 3H, Ar), 4.99–5.20 (m, 2H, CH2N),
4.92–4.95 (m, 2H, CH2N), 2.80–2.86 (m, 2H, CH2) ppm;
13C NMR (100 MHz, DMSO-d6): d = 163.38, 142.25,
131.22, 130.29, 127.18, 126.08, 125.59, 125.39, 118.04,
113.32, 55.10, 50.96, 28.20 ppm; IR (nujol): v = 1579,
1525, 1512, 1452, 1426, 1178, 1124, 1083, 1045, 975 cm-1;
HRMS (ESI-TOF): m/z = 6217295 ([M ? 1]?).
2-[3-[5-(4-Methylphenyl)-2H-tetrazol-2-yl]propyl]-2H-
benzotriazole (8b, C17H13Br4N7)
Yield 0.145 g (46 %); colorless crystals; m.p.:
177–178 C; 1H NMR (400 MHz, DMSO-d6):
d = 7.47–7.49 (m, 2H, Ar), 7.17–7.19 (m, 2H, Ar),
4.98–5.01 (m, 2H, CH2N), 4.91–4.94 (m, 2H, CH2N),
2.80–2.85 (m, 2H, CH2), 2.35 (s, 3H, CH3) ppm;
13C NMR
(100 MHz, DMSO-d6): d = 163.28, 142.14, 139.92,
129.26, 125.34, 123.16, 113.22, 55.25, 51.06, 28.22,
21.18 ppm; IR (nujol): v = 1449, 1430, 1178, 1130,
1067, 1045, 975 cm-1; HRMS (ESI-TOF): m/z =
635.7364 ([M ? 1]?).
2-[3-[5-(4-Chlorophenyl)-2H-tetrazol-2-yl]propyl]-2H-
benzotriazole (8c, C16H10Br4ClN7)
Yield 0.173 g (54 %); colorless crystals; m.p.:
193–195 C; 1H NMR (400 MHz, CDCl3):
d = 7.89–7.91 (m, 2H, Ar), 7.41–7.45 (m, 2H, Ar),
4.93–4.96 (m, 2H, CH2N), 4.85–4.88 (m, 2H, CH2N),
2.95–3.02 (m, 2H, CH2) ppm;
13C NMR (100 MHz,
CDCl3): d = 164.15, 143.12, 136.53, 129.12, 127.75,
126.72, 125.09, 113.61, 54.73, 50.63, 28.80 ppm; IR
(nujol): v = 1636, 1601, 1560, 1531, 1442, 1356, 1176,
1165, 1127, 1096, 1076, 1038, 1013, 981 cm-1; HRMS
(ESI-TOF): m/z = 655.7704 ([M ? 1]?).
2-[3-[5-(2-Chlorophenyl)-2H-tetrazol-2-yl]propyl]-2H-
benzotriazole (8d, C16H10Br4ClN7)
Yield 0.2 g (63 %); colorless crystals; m.p.: 153–154 C;
1H NMR (400 MHz, DMSO-d6): d = 7.69–7.71 (m, 1H,
Ar), 7.41–7.57 (m, 3H, Ar), 4.99–5.20 (m, 2H, CH2N),
4.95–4.99 (m, 2H, CH2N), 2.78–2.86 (m, 2H, CH2) ppm;
13C NMR (100 MHz, DMSO-d6): d = 161.82, 142.34,
131.68, 131.41, 130.69, 130.62, 127.28, 125.43, 125.21,
113.45, 54.83, 50.81, 28.19 ppm; IR (nujol): v = 1608,
1573, 1528, 1445, 1426, 1200, 1172, 1130, 1070, 1045,
981 cm-1; HRMS (ESI-TOF): m/z = 655.6667
([M ? 1]?).
Cell culture and treatment
MCF-7 adherent cells (human breast adenocarcinoma line)
were cultured in DMEM medium with high glucose
(Gibco), supplemented with 10 % fetal bovine serum
(Gibco), 2 mM L-glutamine, antibiotics (100 U/cm3 peni-
cillin, 100 lg/cm3 streptomycin) and 10 lg/cm3 of human
recombinant insulin. CCRF-CEM cell suspension (human
T lymphoblast cell line) was cultured in RPMI 1640
medium (Gibco) supplemented with 10 % fetal bovine
serum and antibiotics (100 U/cm3 penicillin, 100 lg/cm3
streptomycin). Cells were grown in 25 cm2 culture flasks
(Sarstedt), in a humidified atmosphere of CO2/air (5/95 %)
at 37 C.
MTT cytotoxicity assay
MCF-7 cells were collected by trypsinization (0.25 %
trypsin–EDTA solution, Sigma-Aldrich) and seeded into
96-well microplates at density 1.5–3 9 104 cells/well. At
70 % of confluency (18 h after plating) cells were treated
with various concentrations of investigated compounds
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dissolved in DMSO (0.5 %) or DMSO (0.5 %) alone
(control). CCRF-CEM cells were seeded at 2–3 9 104
cells/well and treated with compounds. MTT stock solution
(Sigma-Aldrich) was added to each well to a final con-
centration of 0.5 mg/cm3. After 4 h incubation at 37 C,
formazan crystals were dissolved in DMSO (200 mm3)
(37 C, 10 min incubation), and Sorensen’s glycine buffer
(0.1 M glycine, 0.1 M NaCl, pH 10.5) was added to each
well (25 mm3/well). Optical densities were measured at
570 nm using BioTek microplate reader. All measurements
were carried out in triplicates and the results are expressed
as percentage of cell viability relative to control (cells in
0.5 % DMSO). At such conditions, IC50 for antitumor
antibiotic doxorubicin was 1.4 lM for both MCF-7 and
CCRF-CEM lines.
CK2a assay
CK2a was expressed and purified according to an earlier
published procedure [28]. Isotopic assay was used to
determine CK2a activity with synthetic peptide substrate
(RRRDDDSDDD) from Biaffin GmbH & Co KG, Ger-
many. Experiments were carried out at 30 C for 20 min in
the presence of the increasing concentrations of inhibitors.
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